23.45
+1.91%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chengdu Kanghong Pharmaceutical Group Co
Its shares trade on Shenzhen under the ticker 002773.SZ. It has been listed since 26 June 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.59bn and net income of CN¥1.16bn. At that date it held total assets of CN¥9.92bn and shareholders' equity of CN¥9.30bn.
Chengdu Kanghong Pharmaceutical Group Co., Ltd. engages in the research, manufacture and distribution of biological products, traditional Chinese medicines, and chemical drugs. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2015-06-26. The Company’s main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Jun 2015
- Employees
- 4,045
- Website
- cnkh.com ↗
Leadership
Pay as last reported
- Mr. Zunhong KeChairman of the Board, since 1998CN¥1.3m
- Mr. Xiao KePresident, Director, since 2010CN¥2.1m
- Mr. Jianjun ZhongChief Financial Officer, Vice PresidentCN¥3.0m
- Ms. Yanhua XuExecutive Vice PresidentCN¥4.0m
- Mr. Jinqun YinVice President, Director, since 2013CN¥5.8m
- Ms. Jianrong ZhongVice President, Director, since 2008CN¥1.9m
- Mr. Kang DengSecretary of the BoardCN¥1.8m
- Mr. Lin WangDirector
- Mr. Zhirong ZhangDirector
- Mr. Hongguang DengIndependent DirectorCN¥120,000
- Ms. Nan XuIndependent DirectorCN¥120,000
- Mr. Demin ZhouIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 70
- Environment
- 99
- Social
- 63
- Governance
- 48
- Direct emissions (scope 1)
- 12,940.6 t
- Energy emissions (scope 2)
- 4,993.08 t
- Women in the workforce
- 48.3%
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chengdu Kanghong Pharmaceutical Group Co Ltd employs 4045 full-time staff members.
- The company distributes its products in the domestic market effectively.
- Main products include Conbercept Ophthalmic Injection and Songling capsules for blood vessels.
Weaknesses
- The firm relies solely on the domestic market for product distribution.
- Chengdu Kanghong Pharmaceutical Group Co Ltd has limited international presence currently.
- Only domestic market distribution channels are utilized by the company.
Opportunities
- Expanding distribution of Conbercept Ophthalmic Injection into international markets is possible.
- Growing demand for traditional Chinese medicines offers growth potential for the firm.
- Introducing chemical drugs like venlafaxine hydrochloride capsules to new regions could help.
Threats
- Dependence on the domestic market exposes the company to local economic shifts.
- Competitors in the pharmaceutical sector may capture market share from Chengdu Kanghong.
- Regulatory changes in China could impact the distribution of biological products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.